503A vs 503B Pharmacies: The Distinction That Decides Your Peptide Access
One section of federal law is opening a door for peptides like BPC-157. The other is closing one for compounded GLP-1s. Understanding the difference between 503A and 503B compounding is the single most important regulatory concept in the peptide space right now.
Every article about peptide access, every provider comparison, every discussion about compounded semaglutide eventually runs into the same two numbers: 503A and 503B. They refer to sections of the Federal Food, Drug, and Cosmetic Act that define how compounding pharmacies are allowed to operate. They sound like bureaucratic footnotes. They are, in fact, the infrastructure that determines whether you can legally access a compounded peptide, who makes it, how it’s tested, and what happens to the market when the FDA tightens or loosens the rules.
In 2026, these two sections are moving in opposite directions. The 503A pathway is expanding: six peptides received favorable PCAC recommendations in July for inclusion on the 503A Bulks List. The 503B pathway is contracting: the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List in April, and the comment period closed in July.
Understanding this distinction is not optional if you are trying to access peptide therapy, evaluating a provider, or making sense of the regulatory news. Here is the full breakdown.
The Core Difference
Traditional compounding pharmacy. Prepares medications for individual patients based on specific prescriptions. Regulated primarily by state boards of pharmacy. Cannot produce in large batches or for general office use.
Think: your pharmacist mixes a custom medication just for you, based on your doctor’s prescription.
Outsourcing facility. Can produce compounded medications in large batches without patient-specific prescriptions. Federally regulated by the FDA. Must comply with current Good Manufacturing Practices (cGMP), the same standards as pharmaceutical manufacturers.
Think: a mini drug manufacturer that supplies hospitals, clinics, and doctors’ offices with ready-made compounded medications.
Both exist because not every patient’s needs can be met by commercially available, FDA-approved drugs. A patient might need a different dosage, a different delivery method, an allergen-free formulation, or a substance that has no FDA-approved version. Compounding fills those gaps. Sections 503A and 503B define the two legal frameworks under which it can happen.
Side-by-Side Comparison
| Attribute | 503A Pharmacy | 503B Facility |
|---|---|---|
| Prescription Required | Yes — patient-specific prescription before compounding | No — can compound in advance without individual prescriptions |
| Primary Regulator | State board of pharmacy | FDA (federal) |
| FDA Registration | Not required | Required — must register and submit to FDA inspections |
| Manufacturing Standards | USP 795 (non-sterile) and USP 797 (sterile) | cGMP (21 CFR Part 210/211) — same as pharmaceutical manufacturers |
| Batch Production | Limited — typically 30-day supply per patient | Large batches permitted |
| Office Use / Distribution | Not permitted | Permitted — can supply hospitals, clinics, physicians |
| End-Product Testing | Not required by federal law (state rules vary) | Required — sterility, potency, and stability validation |
| Beyond-Use Dating | Shorter (based on USP guidelines, not formal stability testing) | Longer (based on validated stability data) |
| Bulks List | 503A Bulks List (21 C.F.R. § 216.23) | 503B Bulks List (separate list) |
| 2026 Direction | Expanding — 6 peptides recommended for inclusion | Contracting — GLP-1 drugs proposed for exclusion |
Why This Matters for Peptides
The 503A Bulks List is the only legal pathway for compounding peptides like BPC-157, TB-500, Semax, and the other substances reviewed by the PCAC in July 2026. Here is why.
For a compounding pharmacy to legally use a substance, that substance must meet one of three criteria. It must have an applicable USP or National Formulary monograph. It must be a component of an FDA-approved drug. Or it must appear on the 503A Bulks List. For peptides like BPC-157, the first two do not apply. There is no USP monograph. There is no FDA-approved drug containing BPC-157. That leaves the 503A Bulks List as the only route.
This is why the PCAC vote was significant: six of seven peptides were recommended for that list. And it is why the formal rulemaking process matters: until the FDA actually places these substances on the list through notice-and-comment rulemaking, the legal authorization is incomplete.
In the interim, the FDA’s Category 1 enforcement framework provides a practical pathway: the agency has signaled it will not pursue enforcement against licensed 503A pharmacies compounding Category 1 substances with a valid prescription. Some providers are operating under this framework now. For how that works in practice, see our guide on how to get peptides prescribed.
Why This Matters for GLP-1s
While the 503A peptide pathway is expanding, the 503B GLP-1 pathway is closing. On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances.
The context: during the GLP-1 shortage period (2022–2025), compounded versions of these weight-loss drugs accounted for roughly 30% of total U.S. supply. That was enabled by two regulatory mechanisms — the drugs appearing on the FDA shortage list and the possibility of 503B bulks list inclusion. Both doors have now closed. The tirzepatide shortage was resolved in December 2024. The semaglutide shortage was resolved in February 2025. And the proposed exclusion would permanently bar 503B facilities from compounding these substances, even in future shortages.
The public comment period, extended once by 30 days, closed on July 30, 2026. A final rule is expected in the coming months.
What about 503A pharmacies compounding GLP-1s? The pathway is much narrower. Patient-specific compounding based on documented medical necessity — where the commercially available brand-name product genuinely cannot meet an individual patient’s needs — remains a recognized framework under 503A. But this is not the broad access that existed during the shortage. The prescription must reflect a genuine, individualized clinical determination, and the FDA has issued clarifications on what constitutes sufficient justification.
This matters for the peptide market because many telehealth companies that built businesses around compounded semaglutide and tirzepatide are now pivoting toward non-GLP-1 peptides. The PCAC recommendations for BPC-157, MOTS-c, and others have taken on additional commercial significance in this context.
The 2012 Disaster That Created 503B
The 503B outsourcing facility category did not always exist. It was created by the Drug Quality and Security Act of 2013, in direct response to the New England Compounding Center (NECC) meningitis outbreak of 2012.
NECC, a Massachusetts compounding pharmacy, shipped contaminated steroid injections to clinics across the country. The contamination caused a fungal meningitis outbreak that killed 76 people and sickened over 750. It was the worst pharmaceutical disaster in modern U.S. history, and it exposed a regulatory gap: state-regulated compounding pharmacies were producing medications at an industrial scale, distributing them nationally, but operating without FDA manufacturing oversight.
Congress responded by creating Section 503B, a new category for facilities that wanted to compound at scale. These outsourcing facilities would register with the FDA, submit to federal inspections, and comply with cGMP — the same manufacturing standards as major pharmaceutical companies. In exchange, they could produce large batches without patient-specific prescriptions and distribute directly to healthcare facilities.
The distinction between 503A and 503B, then, is not bureaucratic hairsplitting. It was written in response to patient deaths and designed to separate patient-specific pharmacy practice from industrial-scale drug production.
How to Verify a Compounding Pharmacy
Whether you are getting a peptide compounded under the Category 1 framework or filling any other compounded prescription, verifying your pharmacy’s legitimacy is a safety decision. Here is what to check for each type.
For a 503A Pharmacy
For a 503B Outsourcing Facility
A pharmacy that does not require a prescription. A seller that ships peptides labeled “for research use only” while implying human use. A facility that cannot produce a COA for its raw materials. A 503B that is not listed in the FDA’s outsourcing facility database. Any of these should end the conversation.
The Two Bulks Lists
Each section of law has its own bulks list, and they operate independently.
The 503A Bulks List (21 C.F.R. § 216.23) identifies substances that licensed compounding pharmacies may use to prepare patient-specific prescriptions. For substances that are not in an FDA-approved drug and have no USP monograph — which describes every peptide in the current discussion — this list is the only legal pathway. This is the list the PCAC recommended adding BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax to. Placement requires FDA rulemaking.
The 503B Bulks List identifies substances that outsourcing facilities may use for large-scale compounding. This is the list the FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from. Exclusion means outsourcing facilities cannot compound these drugs from bulk substances unless they are on the shortage list at the time of compounding.
The two lists serve different facility types, follow different regulatory procedures, and are currently moving in different directions. A substance can be on one list, both lists, or neither. The peptides recommended by the PCAC were evaluated only for the 503A list.
What This Means for Patients
If you are trying to access a peptide like BPC-157, the pathway runs through 503A. You need a prescribing provider, baseline bloodwork, and a licensed 503A compounding pharmacy. The Category 1 enforcement framework means this pathway is practically available now, even though formal 503A listing is pending. Our step-by-step guide covers the process.
If you have been using compounded semaglutide or tirzepatide for weight management, the regulatory landscape has changed substantially. The broad access that existed during the shortage period is over. Remaining options include brand-name FDA-approved products (Ozempic, Wegovy, Mounjaro, Zepbound), the newly approved oral GLP-1 orforglipron (Foundayo), and narrower 503A patient-specific compounding where genuine medical necessity is documented.
In both cases, the quality of your pharmacy matters more than the regulatory label. A well-run 503A pharmacy with PCAB accreditation, proper sterility controls, and verified raw materials is safer than a poorly run 503B with outstanding Form 483 citations. The category tells you about the regulatory framework. The pharmacy’s actual practices tell you about the product you receive.
Frequently Asked Questions
Sources
This article draws on Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act; 21 C.F.R. § 216.23 (503A Bulks List); the FDA’s April 30, 2026 proposed rule on GLP-1 503B exclusion (docket 2026-08552); the July 23–24, 2026 PCAC meeting record (docket FDA-2025-N-6895); regulatory analysis from Pharmacy Times, Orrick, Frier Levitt, Epstein Becker Green, and McDermott Will & Emery; the Drug Quality and Security Act of 2013; and the FDA’s outsourcing facility registration database.